title: Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
abstract: Epstein-Barr virus (EBV) infections, associated with posttransplant lymphoproliferative disorder (PTLD) are known to develop in cytomegalovirus (CMV)-infected transplant recipients due to the indirect effects of CMV. This study evaluated risk factors for PTLD among pediatric liver transplant recipients with CMV infections. We reviewed the medical records of 119 patients<or=18 years old who underwent liver transplantation between September 1996 and April 2009. Sixty-six subjects (55.5%) displayed CMV antigenemia during the study period; 15 (12.6%) developed PTLD. Of these, 10 developed PTLD after CMV antigenemia. The other patients (n=5) were excluded due to negative CMV antigenemia. The incidence of PTLD influenced by CMV infection was not significantly different from the incidence of PTLD without underlying CMV (P=.258). There were no differences in age, gender, antiviral prophylaxis, type of liver transplantation, or acute rejection episodes in the incidence of between patients with versus without PTLD. EBV but not CMV high-risk groups were a predictor for the development of PTLD (P=.035). CMV syndrome, tissue-invasive CMV disease, and CMV peak titer were not associated with an increased risk of PTLD. The primary risk factor for PTLD was EBV high-risk patients (donor positive/recipient negative). CMV disease was not associated with PTLD in pediatric liver transplant recipients with CMV infections.
authors.affiliation: Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: J M
authors.initials: JM
authors.lastname: Kim
authors.forename: S-K
authors.initials: SK
authors.lastname: Lee
authors.forename: S J
authors.initials: SJ
authors.lastname: Kim
authors.forename: J-W
authors.initials: JW
authors.lastname: Joh
authors.forename: C H D
authors.initials: CH
authors.lastname: Kwon
authors.forename: Y H
authors.initials: YH
authors.lastname: Choe
authors.forename: M
authors.initials: M
authors.lastname: Shin
authors.forename: E Y
authors.initials: EY
authors.lastname: Kim
authors.forename: J I
authors.initials: JI
authors.lastname: Moon
authors.forename: G O
authors.initials: GO
authors.lastname: Jung
authors.forename: G-S
authors.initials: GS
authors.lastname: Choi
mesh_terms: D000293:Adolescent; D000956:Antigens, Viral / Q000097:blood*; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000453:epidemiology* / Q000821:virology; D008297:Male; D012307:Risk Factors
chemical_list: D000956:Antigens, Viral; D000998:Antiviral Agents